NCT07737457Not yet recruiting
MICRO-ultrasound Guided Prostate SBRT
MICRO-ultrasound Guided Prostate SBRT (MICRO-S)
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots inside the prostate. Researchers will compare treatment plans that use microUS to plans created using the current standard method, which relies on MRI images, to determine whether microUS can successfully guide targeted radiation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- Sept 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Diseases
- Prostate cancer
- NCT number
- NCT07737457
What you commit to
- Study type: Interventional
- Planned participants: 112
- From Sept 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior TURP
- Prior prostate cancer treatment, including 5-alpha reductase inhibitor treatment
- Anticoagulation medication (if unsafe to discontinue for fiducial marker insertion)
Other illness
- Low, high or very high-risk disease as per NCCN guidelines
- Connective tissue disease or inflammatory bowel disease
- Diagnosis of bleeding diathesis
Other
- Estimated prostate volume \> 60cc (volume based on transrectal ultrasound)
- Contraindication to prostate microUS
- Men with double hip prostheses
- Contraindication for MRI (i.e. non-compatible stent, pacemaker, prosthesis etc.)
Who the study is looking for
- Histologically confirmed carcinoma of the prostate (biopsy results with 12 months of enrollment)
- Intermediate risk as defined by NCCN criteria
- Conventional imaging (bone scan and abdominal pelvic computed tomography) is mandatory for NCCN unfavourable intermediate risk prostate cancer patients with PSA \> 10. Negative nodal, skeletal or visceral metastases within 16 weeks of enrollment (for patients requiring staging). Alternatively, patients with no signs of extra-prostatic disease on PSMA-PET scans are also candidates for this trial
- ECOG performance status 0-1
- Willing to give informed consent to participate in this clinical trial
- Able and willing to complete QOL questionnaires Most responsive physician definition if androgen deprivation therapy will be used (only allowed for NCCN unfavourable intermediate risk prostate cancer)
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| London Health Sciences Centre - Verspeeten Family Cancer Centre Coordinator of this site? Confirm its status | London | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.